ArticleClinical epidemiology2020
Existing Data Sources for Clinical Epidemiology: The PHARMO Database Network.
Article in Clinical epidemiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Availability of Evidence for Predictive Machine Learning Algorithms in Primary Care: A Systematic Review.JAMA network open · 2024Pooled it
- Development of Indirect Health Data Linkage on Health Product Use and Care Trajectories in France: Systematic Review.Journal of medical Internet research · 2023Pooled it
- Sex differences in single and combined cardiovascular medication use.American heart journal plus : cardiology research and practice · 2026Article
- GP Consultations for Herpes Zoster After COVID-19 Vaccination: A Self-Controlled Cohort Study Based on Electronic Health Record Data from the Netherlands.Drug safety · 2026Article
- Real-world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network.Diabetes, obesity & metabolism · 2026 · on this mapObservational
- GP Consultations for Venous Thromboembolism (VTE) After mRNA and Adeno-Vector-Based COVID-19 Vaccination-An Exposure-Anchored Self-Controlled Cohort Study Based on Primary Healthcare Data From the Netherlands.Pharmacoepidemiology and drug safety · 2026Article
- Uptitration of statin therapy in women and men: a population-based cohort study.European heart journal. Quality of care & clinical outcomes · 2025Article
- General practitioner consultation for postmenopausal bleeding after COVID-19 vaccination-a self-controlled cohort study.British journal of clinical pharmacology · 2025Article
- Tailoring remote patient management to optimise cardiovascular risk management in primary care: a mixed-methods implementation study informing large-scale implementation.BMC primary care · 2025Article
- Article
- Impact of Pharmacovigilance Interventions Targeting Fluoroquinolones on Antibiotic Use in the Netherlands and the United Kingdom.Pharmacoepidemiology and drug safety · 2025Article
- Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Trends in initial pharmacological COPD treatment in primary care (2010-2021): a population-based study using the PHARMO Data Network.Respiratory research · 2024Article
- Antibiotic Utilization Among People With Multiple Sclerosis in the Netherlands, 2018-2020.Pharmacoepidemiology and drug safety · 2024Article
- Impact of implementing Dutch versus European guideline risk factor targets in older patients with ischaemic heart disease.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2024Article
- Type 2 Diabetes, the Epidemic: Trends in Prevalence and Incidence, 2004-2020.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Risk of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: results from the EXACOS-CV cohort study using the PHARMO Data Network in the Netherlands.Respiratory research · 2023Article
- Prevalence of chronic kidney disease in the Netherlands and its cardiovascular and renal complications.BMC nephrology · 2023Article
- Identification of frailty in primary care: accuracy of electronically derived measures.The British journal of general practice : the journal of the Royal College of General Practitioners · 2023Article
- Added Predictive Value of Female-Specific Factors and Psychosocial Factors for the Risk of Stroke in Women Under 50.Neurology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The PHARMO Database Network provides a unique opportunity to gain insight in the complete patient journey and healthcare in the Netherlands. The PHARMO Database Network is a population-based network of electronic healthcare databases and combines anonymous data from different primary and secondary healthcare settings in the Netherlands. Healthcare settings include general practitioners, out-patient and in-patient pharmacies, hospitals and clinical laboratories. Furthermore, databases are linked with external registries such as the Cancer Registry, Pathology Registry and Perinatal Registry. The different data sources are linked on a patient level through probabilistic linkage based on validated algorithms. The longitudinal and ongoing nature of the PHARMO Database Network system enables to follow up more than 10 million residents of the Netherlands for an average of 12 years. Data collection period, catchment area and overlap between data sources differ. Access to the PHARMO Database Network is, by governance regulations of the data collection, restricted to researchers of the PHARMO Institute and academic affiliates. Each data request is checked against privacy and company policies, and requires approval of the privacy and governance board. The terms and conditions and a data application form are available on the PHARMO website (www.pharmo.com).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.